|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | RTOG 0211:a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients显示文摘PURPOSE: To determine the safety and efficacy of gefitinib,an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor,in combination with radiation for newly diagnosed glioblastoma(GBM) patients.METHODS AND MATERIALS: Between March 21,2002,and May 3,2004,Radiation Therapy Oncology Group(RTOG) 0211 enrolled 31 and 147GBM patients in the phase 1 and 2 arms,respectively.Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy(RT) and continued post RT for 18 months or until progression.Tissue microarrays from 68 cases were analyzed for EGFR expression.RESULTS: The maximum tolerated dose(MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs(non-EIAEDs).All patients in the phase 2 component were treated at a gefitinib dose of 500 mg;patients receiving EIADSs could be escalated to 750 mg.The most common side effects of gefitinib in combination with radiation were dermatologic and gastrointestinal.Median survival was 11.5 months for patients treated per protocol.There was no overall survival benefit for patients treated with gefitinib + RT when compared with a historical cohort of patients treated with RT alone,matched by RTOG recursive partitioning analysis(RPA) class distribution.Younger age was significantly associated with better outcome.Per protocol stratification,EGFR expression was not found to be of prognostic value for gefitinib + RT-treated patients.CONCLUSIONS: The addition of gefitinib to RT is well tolerated.Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone. | Chakravarti A Wang M Robins HI Lautenschlaeger T Curran WJ Brachman DG Schultz CJ Choucair A Dolled-Filhart M Christiansen J Gustavson M Molinaro A Mischel P Dicker AP Bredel M Mehta M | 2013 | 中国神经肿瘤杂志2013，11，1： | 8 |
| 2 | Haloperidol-loaded in- tranasally administered lectin functionalized poly (ethylene glycol )-block-poly ( d, 1 )-lactic-co-glycolic acid ( PEG-PL- GA) nanoparticles for the treatment of schizophrenia显示文摘 | Piazza J Hoare T Molinaro L | 2014 | Eur J Pharm Biopharm2014，87，1： | 1 |
| 3 | Priming,Induction and Modulation of Plant Defence Responses by Bacterial Lipopolysaccharides显示文摘 | NEWMAN M A DOW J M MOLINARO A | 2007 | J Endotoxin Res2007，13，2： | 1 |
| 4 | Hemodynamic effects of carbon dioxide insufflation during endoscopic vein harvesting 显示文摘 | Vitall RM Reddy RC Molinaro J | 2000 | The Annals of Vascular Surgery2000，70，： | 1 |
| 5 | Bioeompatibility of thermosensi- tive chitosan-based hydrogels:an in vivo experimental approach to in- jectable biomaterials 显示文摘 | Molinaro G Leroux JC Damas J | 2002 | Biomaterials2002，23，： | 1 |
| 6 | Biocompalibility of thermosensitive chitosan-based hydrogels: an in vivo experimental ap-proach to injectable biomalerials 显示文摘 | Molinaro G Leroux JC Damas J | 2002 | Bio natcrials2002，23，13： | 1 |
| 7 | Biocompatibility of thermosensitive chitosan-based hydrogels: An in vivo experimental approach to injectable biomaterials 显示文摘 | Molinaro G Leroux J C Damas J | 2002 | Biomaterials2002，23，13： | 1 |
| 8 | Glioma groups based on lp/19q, IDH, and TERT promoter mutations in tumors显示文摘 | Eckel-Passow J E Lachance D H Molinaro A M | 2015 | N Engl J Med2015，372，26： | 1 |
| 9 | The syndrome of amniotic fluid embolism: a potential contribution of bradykinin 显示文摘 | Robillard J Gauvin F Molinaro G | 2005 | Am J Obstet Gynecol2005，193，： | 1 |
| 10 | Identification of-a novel Gammaretrovirus in prostate tumors of patients hom-ozygous for R462Q RNASEL variant 显示文摘 | Urisman A Molinaro R J Fischer N | 2006 | PLoS Pathog2006，2，3： | 1 |
| 11 | Biocompatibility of thermosensitive chitosan-based hydrogels : an in vivo experimental approach to injectable biomaterials显示文摘 | Molinaro G Leroux JC Damas J | 2002 | Biomaterials2002，23，13： | 1 |
| 12 | Bioeompatibility of ther- mosensitive chitosan-based hydrogds:an in vivo experimental approach to injectable biomaterials显示文摘 | Molinaro G Leroux J C Damas J | 2002 | Biomaterials2002，23，13： | 1 |
| 13 | Biocompatibility of thermo-sensitive chitosan梑ased hydrogels:an in vivo experimental approach to injectable biomaterials显示文摘 | Molinaro G Leroux JC Damas J Adam A | 2002 | Biomaterials2002，23，： | 1 |
| 14 | HLA antigens associated with susceptibility/resistance to HIV-1 infection显示文摘 | Rohowsky C Skurnick J Molinaro | 1998 | Hum Immunol1998，59，： | 1 |
| 15 | Biocompatibility of thermosensitive chitosan-based hydrogels: An in vivo experimental approach to injectable biomaterials显示文摘 | Molinaro G Leroux JC Damas J | 2002 | Biomaterials2002，23，13： | 1 |
| 16 | Localization and quantitation of eotaxin mRNA in human nasal polyps显示文摘 | Molinaro R J Bernstein J M Koury S T | 2003 | Immunol Invest2003，32，3： | 1 |
| 17 | ChemBioChem显示文摘 | Marchetti R Canales A Lanzetta R Nilsson I Vogel C Reed D E AuCoin D P Barbero J J Molinaro A Silipo A | 2013 | 14(12):14852013，14，12： | 1 |
| 18 | Localization and quantitation of Eotaxin mRNA in human nasal polyps 显示文摘 | Molinaro R J Bemstein J M Koury S T | 2003 | Immunol Invest2003，32，3： | 1 |
| 19 | The syndrome of amniotic fluide mbolismand:apotential contribution of bradykinin显示文摘 | Rolillard J Gauvin if Molinaro G | 2005 | AmJObstet Gynecol2005，193，： | 1 |
| 20 | The syndrome of amniotic fluide mbolismand : apo- tential contribution of bradykinin显示文摘 | Rolillard J Gauvin F Molinaro G | 2005 | AmJOb- stet Gyneco12005，193，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员